RPRX Annual CFF
-$2.15 B
-$1.20 B-127.42%
31 December 2023
Summary:
As of January 20, 2025, RPRX annual cash flow from financing activities is -$2.15 billion, with the most recent change of -$1.20 billion (-127.42%) on December 31, 2023. During the last 3 years, it has fallen by -$3.64 billion (-244.49%). RPRX annual CFF is now -244.49% below its all-time high of $1.49 billion, reached on December 31, 2020.RPRX Cash From Financing Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX Quarterly CFF
-$325.50 M
-$1.48 B-128.14%
30 September 2024
Summary:
As of January 20, 2025, RPRX quarterly cash flow from financing activities is -$325.50 million, with the most recent change of -$1.48 billion (-128.14%) on September 30, 2024. Over the past year, it has dropped by -$113.51 million (-53.54%). RPRX quarterly CFF is now -120.61% below its all-time high of $1.58 billion, reached on June 30, 2020.RPRX Quarterly CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX TTM CFF
$387.21 M
+$1.03 B+159.87%
30 September 2024
Summary:
As of January 20, 2025, RPRX TTM cash flow from financing activities is $387.21 million, with the most recent change of +$1.03 billion (+159.87%) on September 30, 2024. Over the past year, it has increased by +$2.54 billion (+118.01%). RPRX TTM CFF is now -75.11% below its all-time high of $1.56 billion, reached on June 30, 2020.RPRX TTM CFF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
RPRX Cash From Financing Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -127.4% | -53.5% | +118.0% |
| 3 y3 years | -244.5% | -53.5% | +118.0% |
| 5 y5 years | -55.8% | -16.0% | +132.5% |
RPRX Cash From Financing High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -658.0% | at low | -128.1% | +76.1% | -0.9% | +117.7% |
| 5 y | 5-year | -244.5% | at low | -120.6% | +76.1% | -75.1% | +117.7% |
| alltime | all time | -244.5% | at low | -120.6% | +76.1% | -75.1% | +117.7% |
Royalty Pharma Cash From Financing History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$325.50 M(-128.1%) | $387.21 M(-159.9%) |
| June 2024 | - | $1.16 B(-645.6%) | -$646.77 M(-69.9%) |
| Mar 2024 | - | -$212.00 M(-8.6%) | -$2.15 B(+0.1%) |
| Dec 2023 | -$2.15 B(+127.4%) | -$231.89 M(-82.9%) | -$2.15 B(-1.5%) |
| Sept 2023 | - | -$1.36 B(+291.8%) | -$2.18 B(+107.3%) |
| June 2023 | - | -$347.00 M(+64.9%) | -$1.05 B(+12.7%) |
| Mar 2023 | - | -$210.37 M(-20.8%) | -$934.26 M(-1.1%) |
| Dec 2022 | -$944.86 M(-345.3%) | -$265.55 M(+15.4%) | -$944.86 M(+7.7%) |
| Sept 2022 | - | -$230.09 M(+0.8%) | -$877.38 M(-326.7%) |
| June 2022 | - | -$228.25 M(+3.3%) | $386.98 M(-1.0%) |
| Mar 2022 | - | -$220.97 M(+11.6%) | $390.82 M(+1.5%) |
| Dec 2021 | $385.11 M | -$198.07 M(-119.2%) | $385.11 M(+25.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2021 | - | $1.03 B(-560.9%) | $305.79 M(-128.2%) |
| June 2021 | - | -$224.41 M(-1.0%) | -$1.09 B(-251.2%) |
| Mar 2021 | - | -$226.67 M(-18.3%) | $717.98 M(-51.7%) |
| Dec 2020 | $1.49 B(-224.8%) | -$277.39 M(-22.4%) | $1.49 B(+0.6%) |
| Sept 2020 | - | -$357.39 M(-122.6%) | $1.48 B(-4.9%) |
| June 2020 | - | $1.58 B(+191.1%) | $1.56 B(-565.5%) |
| Mar 2020 | - | $542.52 M(-289.8%) | -$334.15 M(-72.0%) |
| Dec 2019 | -$1.19 B(-13.6%) | -$285.80 M(+1.8%) | -$1.19 B(+31.6%) |
| Sept 2019 | - | -$280.69 M(-9.5%) | -$905.82 M(+44.9%) |
| June 2019 | - | -$310.18 M(-1.5%) | -$625.13 M(+98.5%) |
| Mar 2019 | - | -$314.96 M | -$314.96 M |
| Dec 2018 | -$1.38 B(+1018.9%) | - | - |
| Dec 2017 | -$123.25 M | - | - |
FAQ
- What is Royalty Pharma annual cash flow from financing activities?
- What is the all time high annual CFF for Royalty Pharma?
- What is Royalty Pharma annual CFF year-on-year change?
- What is Royalty Pharma quarterly cash flow from financing activities?
- What is the all time high quarterly CFF for Royalty Pharma?
- What is Royalty Pharma quarterly CFF year-on-year change?
- What is Royalty Pharma TTM cash flow from financing activities?
- What is the all time high TTM CFF for Royalty Pharma?
- What is Royalty Pharma TTM CFF year-on-year change?
What is Royalty Pharma annual cash flow from financing activities?
The current annual CFF of RPRX is -$2.15 B
What is the all time high annual CFF for Royalty Pharma?
Royalty Pharma all-time high annual cash flow from financing activities is $1.49 B
What is Royalty Pharma annual CFF year-on-year change?
Over the past year, RPRX annual cash flow from financing activities has changed by -$1.20 B (-127.42%)
What is Royalty Pharma quarterly cash flow from financing activities?
The current quarterly CFF of RPRX is -$325.50 M
What is the all time high quarterly CFF for Royalty Pharma?
Royalty Pharma all-time high quarterly cash flow from financing activities is $1.58 B
What is Royalty Pharma quarterly CFF year-on-year change?
Over the past year, RPRX quarterly cash flow from financing activities has changed by -$113.51 M (-53.54%)
What is Royalty Pharma TTM cash flow from financing activities?
The current TTM CFF of RPRX is $387.21 M
What is the all time high TTM CFF for Royalty Pharma?
Royalty Pharma all-time high TTM cash flow from financing activities is $1.56 B
What is Royalty Pharma TTM CFF year-on-year change?
Over the past year, RPRX TTM cash flow from financing activities has changed by +$2.54 B (+118.01%)